Close
CDMO Safety Testing 2026
Novotech

Adjuvant HER2/neu peptide cancer vaccines in breast cancer

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...
- Advertisement -

Active cancer/peptide cancer immunotherapy remains an exciting and rapidly advancing field in oncology. Peptide cancer vaccines are an attractive therapeutic option as they are safe and easily produced and administered(for breast cancer) .

Peptide cancer vaccines may be most effective in patients with a lower disease burden, when cancer tolerance is minimized. Our experience with three peptide cancer vaccines, E75, GP2 and AE37, in clinically disease-free breast cancer patients provides encouraging results that this method may be effective.

Latest stories

Related stories

Glass vs Polymer: Choosing the Right Material for Parenteral Packaging

In the pharmaceutical industry, material selection plays a critical...

FDA Advances Real-Time Clinical Trials With AstraZeneca, Amgen

The U.S. Food and Drug Administration has unveiled a...

Chiesi Advances Rare Disease Portfolio with KalVista Deal

Chiesi Group has entered into a definitive agreement to...

AstraZeneca UK Investment Resumes with £300m Commitment

In a reversal of its earlier stance, AstraZeneca has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »